Blood Tests for Alzheimer’s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance

The recent academic and commercial development, and regulatory approvals, of blood-based Alzheimer’s disease (AD) biomarkers are breakthrough developments of immense potential. However, clinical validation studies and therapeutic trial applications are limited almost exclusively to non-Hispanic Whit...

Descripción completa

Detalles Bibliográficos
Autor principal: Karikari, Thomas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Ethics Response
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741736/
https://www.ncbi.nlm.nih.gov/pubmed/35491788
http://dx.doi.org/10.3233/JAD-215730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741736/
https://www.ncbi.nlm.nih.gov/pubmed/35491788
http://dx.doi.org/10.3233/JAD-215730

Ejemplares similares